Michael Byrne, PhDVP, Research Pharmacology at Wave Life SciencesSpeaker
Profile
Dr. Byrne has been with Wave Life Sciences, Inc. for eight years where he serves as Vice President of Research Pharmacology. In that time his focus has been on assessing the utility of stereopure oligonucleotides as potential therapeutics for rare genetic diseases through the development of appropriate animal models and drug discovery efforts. Prior to joining Wave, Dr. Byrne spent 9 years at RXi Pharmaceuticals where he led RXi’s self-delivering siRNA oligonucleotides to the clinic for treatment of retinal scarring associated with late-stage AMD. Dr. Byrne received his Ph.D. from Northeastern University in Boston, MA where he studied microRNA expression patterns and impact on embryo development. |
Agenda Sessions
SpiNA siRNA Design Enables Durable Silencing of Inhbe RNA and Fat Loss without Muscle Loss in a Mouse Model of Obesity
, 9:00amView Session